[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-563753-105":53,"doc-detail-563753-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","fosun-international-limited-annual-report-2025-letter-to-shareholders","FOSUN INTERNATIONAL LIMITED Annual Report 2025 - Letter to Shareholders","","Annual Report 2025 for Fosun International Limited, including a financial summary and a formal Letter to Shareholders. The letter provides an open, candid review of the company’s 2025 performance, acknowledging an RMB 23.4 billion loss attributable to owners of the parent. It explains the loss as largely driven by non-cash impairment provisions for certain past development projects, goodwill, and intangible assets, and emphasizes that core businesses such as pharmaceuticals and insurance continued steady growth.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/fosun-international-limited-annual-report-2025-letter-to-shareholders/563753/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/fosun-international-limited-annual-report-2025-letter-to-shareholders/563753.png","ImageObject",442,249,{"name":88,"@type":89},"Aria","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-30","2026-10-12",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",7,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What caused Fosun’s 2025 loss attributable to owners of the parent?","Question",{"text":109,"@type":110},"The letter states the loss was primarily due to prudent recognition of non-cash impairment provisions for certain past development projects, including impairments on goodwill and intangible assets of non-core business segments.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"Does the impairment affect Fosun’s daily operations and cash flow?",{"text":114,"@type":110},"The letter says these provisions will not affect day-to-day operations, cash flow, or business activities.",{"name":116,"@type":107,"acceptedAnswer":117},"Which core businesses continued to grow in 2025?",{"text":118,"@type":110},"Fosun’s core businesses mentioned in the letter—pharmaceuticals and insurance—continued to demonstrate steady growth.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},563753,1792115264,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":136,"language":137,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":61,"update_tm":141,"read_time":142},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","(Incorporated in Hong Kong with limited liability)(Stock Code : 00656)  \n2025  \nANNUAL REPORT  \n|  |  |  |  |  |  |  |  |  |  |  |  |  | | | \u003Cbr>|  | | \u003Cbr>| \u003Cbr>|  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  |  |  |  |  |  |  | |  | |  | | | | |  |  | | | | | | |  |  |  |  |  |  |  |  |  |\n|  | Fi | na | ncial |  | Summa |  | ry |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |\n|  | Le | tte | r t | o S | ha | re | hol |  | de | rs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |\n|  | B | usi | nes | s Overvi |  |  | ew |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7 |  |  |  |  |\n|  | M | an | ag | emen |  | t D | isc |  | us | sio | n & | A | na | lys |  | is |  |  |  |  |  |  |  |  |  |  | 12 |  |  |  |  |\n|  | Five- |  | Ye | ar | Sta | tis | tics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 37 |  |  |  |  |\n|  | C | orp | or | ate | G | ov | ern |  | an | ce | Re | po | rt |  |  |  |  |  |  |  |  |  |  |  |  |  | 38 |  |  |  |  |\n|  | Bi | og | rap | hical |  | D | eta |  | ils of |  | Dir | ect | ors a |  |  | nd | Se | nio | r | Ma | na | ge | me | nt |  |  | 54 |  |  |  |  |\n|  | D | ire | cto | ’rs | Re | po | rt |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 59 |  |  |  |  |\n|  | A | wards |  | and |  | Re | cogni |  |  | tio | n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 | 02 |  |  |  |  |\n|  | In | de | pe | ndent |  | A | udi |  | tor | ’s | Re | po | rt |  |  |  |  |  |  |  |  |  |  |  |  | 1 | 03 |  |  |  |  |\n|  | C | on | sol | ida | ted | S | tat |  | em | en | t o | f Profit |  |  |  | or | Los | s |  |  |  |  |  |  | 1 |  | 09 |  |  |  |  |\n|  | C | on | solida |  | ted | S | tat |  | em | en | t o | f C | o | mp |  | reh | en | siv | e I | nco | m | e |  |  |  | 1 | 10 |  |  |  |  |\n|  | C | on | sol | ida | ted | S | tat |  | em | en | t o | f F | ina | nc |  | ial | Po | siti | on |  |  |  |  |  |  | 112 |  |  |  |  |  |\n|  | C | on | sol | ida | ted | S | tat |  | em | en | t o | f C | ha | ng |  | es | in | Eq | uity |  |  |  |  |  |  | 1 | 14 |  |  |  |  |\n|  | C | on | sol | ida | ted | Stat |  |  | em | en | t o | f C | as | h F |  | lo | ws |  |  |  |  |  |  |  |  | 1 | 18 |  |  |  |  |\n| N |  | ote | s t | o F | in | anc |  | ial | St | ate | men | t | s |  |  |  |  |  |  |  |  |  |  |  |  | 1 | 23 |  |  |  |  |\n|  | C | orp | or | ate | In | fo |  | rmati |  | on |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 | 25 |  |  |  |  |\n|  | G | los | sar | y |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 | 26 |  |  |  |  |\n\nFINANCIAL SUMMARY  \nFor the year ended 31 December  \nRevenue  \nHealth Happiness Wealth  \nInsurance  \nAsset Management Intelligent Manufacturing Eliminations  \n(Loss)/profit attributable to owners of the parent  \nHealth Happiness Wealth  \nInsurance  \nAsset Management Intelligent Manufacturing Eliminations  \nLoss per share – basic (in RMB)  \nLoss per share – diluted (in RMB)  \nDividend per share (in HKD)  \n173,425.3 48,000.0 64,748.4 55,864.9 44,816.7 11,048.2 7,741.4 (2,929.4)  \n(23,395.8) 1,434.9 (9,066.6)(14,173.2) 1,779.2 (15,952.4)  \n(1,546.2)(44.7)  \n(2.88)  \n(2.88)  \n–  \n192,142.0 46,552.9 76,710.1 55,114.1 39,313.8 15,800.3  \n15,585.9 (1,821.0)  \n(4,348.9) 901.1 (1,878.6)(2,656.2) 1,716.1 (4,372.3)(626.8)(88.4)  \n(0.53)  \n(0.53)  \n0.02  \nIn RMB million 2025 2024  \n02  FOSUN INTERNATIONAL LIMITED Annual Report 2025   \nLETTER TO SHAREHOLDERS  \nDear shareholders,  \nToday, I would like to have an open and honest conversation with our shareholders, reflecting on Fosun’s journey in 2025, sharing our thoughts, and outlining where we are heading next.  \nIn 2025, the Company recorded a loss attributable to owners of the parent of RMB23 .4 billion. It should be noted that this loss does not reflect ","cbCaiefDRzINganc","https://ap.wps.com/l/cbCaiefDRzINganc","pdf",6619402,330,"English","# Financial Summary\n## For the year ended 31 December\n# Letter to Shareholders\n## Performance overview and reasons for the loss\n## Core business outlook and strategic focus","[{\"question\":\"What caused Fosun’s 2025 loss attributable to owners of the parent?\",\"answer\":\"The letter states the loss was primarily due to prudent recognition of non-cash impairment provisions for certain past development projects, including impairments on goodwill and intangible assets of non-core business segments.\"},{\"question\":\"Does the impairment affect Fosun’s daily operations and cash flow?\",\"answer\":\"The letter says these provisions will not affect day-to-day operations, cash flow, or business activities.\"},{\"question\":\"Which core businesses continued to grow in 2025?\",\"answer\":\"Fosun’s core businesses mentioned in the letter—pharmaceuticals and insurance—continued to demonstrate steady growth.\"}]","FOSUN INTERNATIONAL LIMITED Annual Report 2025 - Letter to Shareholders | PDF",1791838119,115]